![](/img/cover-not-exists.png)
195TiPSYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
Maurer, C, Eiger, D, Velghe, C, Aftimos, P G, Maetens, M, Gaye, J, Paesmans, M, Ignatiadis, M, Piccart, M, Buisseret, LVolume:
30
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz100.046
Date:
May, 2019
File:
PDF, 80 KB
english, 2019